Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,429.00
+5.50 (0.23%)
Nov 11, 2025, 2:30 PM JST
Kyowa Kirin Employees
Kyowa Kirin had 5,669 employees as of December 31, 2024. The number of employees decreased by 305 or -5.11% compared to the previous year.
Employees
5,669
Change (1Y)
-305
Growth (1Y)
-5.11%
Revenue / Employee
85.06M JPY
Profits / Employee
6.45M JPY
Market Cap
1.27T
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5,669 | -305 | -5.11% |
| Dec 31, 2023 | 5,974 | 222 | 3.86% |
| Dec 31, 2021 | 5,752 | 329 | 6.07% |
| Dec 31, 2020 | 5,423 | 156 | 2.96% |
| Dec 31, 2019 | 5,267 | -1,975 | -27.27% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| HOYA Corporation | 37,909 |
| Otsuka Holdings | 35,338 |
| Olympus | 29,297 |
| Daiichi Sankyo Company | 19,765 |
| M3, Inc. | 15,360 |
| Astellas Pharma | 13,643 |
| Eisai | 10,917 |
Kyowa Kirin News
- 7 days ago - Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - Business Wire
- 11 days ago - Kyowa Kirin reports 9M results - Seeking Alpha
- 11 days ago - Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases - GlobeNewsWire
- 14 days ago - Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan - GlobeNewsWire
- 17 days ago - Kura Oncology Scores $30 Million Boost As New Leukemia Drug Enters Major Trial - Benzinga
- 7 weeks ago - Kura Oncology Transitioning To Commercial Stage: Why I Choose To Buy - Seeking Alpha
- 2 months ago - Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
- 2 months ago - Amgen (AMGN) and Kyowa Kirin Report Positive Long-term Results for Rocatinlimab - GuruFocus